Dr. Tim Bauer

A company’s realizable value is determined long before negotiations begin. Owners who can demonstrate the quality of earnings, cash conversion, growth potential, and risk profile early on lay the foundation for a robust valuation, an attractive pool of buyers, and a controlled sales process. Those who have to wait until they approach the market to make a case for the company’s value find themselves on the defensive during negotiations.

At the beginning of May, enomyc announced its partnership with Ufenau Capital Partners. The objective: to build a leading consulting platform for transformation and restructuring — initially across the German-speaking region, with a clear path toward international reach. In this interview, Julia Hammer, Managing Director of the enomyc Group Holding, explains why the market now requires new consulting models, the role Ufenau will play in the next phase of development, and how enomyc aims to combine growth, entrepreneurship, and platform capability.

The production networks of most medium-sized companies have evolved over time. What may have been sensible and efficient years ago often no longer serves its purpose in an era of volatile demand, fluctuating customer orders, and short product life cycles. For example, if one plant is operating at full capacity while others are underutilized, alarm bells should be ringing in the executive suite. Christian Zeller and Max Stehr explain what companies can do in such situations, when certain measures make sense, and how the production footprint becomes a competitive advantage.

Many business owners first encounter the term IDW S 6 when dealing with banks or financing partners. This often gives the impression that it is a formal report or a regulatory formality for companies in crisis. However, as enomyc author Tom Hammer explains, a restructuring plan in accordance with IDW S 6 can do much more: when intelligently designed and implemented, it ensures clarity in corporate management and builds trust among financing partners—thereby laying the foundation for a sustainably successful future.

Succession, more expensive capital and more selective valuations are increasing the number of complex ownership situations in Germany's industrial Mittelstand. The advantage goes to those who select targets early, finance them through the downside, and create value after closing.

2025 was a challenging year—and a year of professionalization. Many small and medium-sized enterprises (SMEs) refined their business models, adjusted their financing strategies, and tackled technological change more actively than in previous years. We talk to enomyc founders Martin Hammer and Uwe Köstens about key developments and what will be crucial for SMEs in 2026.

With the opening of its US office in Anderson, South Carolina, enomyc is taking an important strategic step in international consulting. In an interview, founder Martin Hammer and Managing Director Franz A. Wenzel explain why local American consulting expertise is a key success factor for the US market, what differences between European and American corporate and work culture are decisive, and how enomyc will provide even more targeted support to medium-sized companies in their global core markets in the future.

The pharmaceutical industry is at a turning point. While global demand for active pharmaceutical ingredients (APIs) is rising, more and more medium-sized manufacturers in Europe are coming under pressure. Skyrocketing location costs and crippling regulations, as well as dependence on Asian suppliers, are making life difficult for them. The market is growing, but not for everyone. In their article, Dr. Stefan Frings and Marius Stenzel explore why some companies are constantly losing ground despite rising demand and what they can do now to adapt their production, supply chains, and organization to the new challenges.